These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 37315289)
1. The role of molecular subtypes and immune infiltration characteristics based on disulfidptosis-associated genes in lung adenocarcinoma. Qi C; Ma J; Sun J; Wu X; Ding J Aging (Albany NY); 2023 Jun; 15(11):5075-5095. PubMed ID: 37315289 [TBL] [Abstract][Full Text] [Related]
2. Multiomics Analysis of Disulfidptosis Patterns and Integrated Machine Learning to Predict Immunotherapy Response in Lung Adenocarcinoma. Liu J; Li H; Zhang N; Dong Q; Liang Z Curr Med Chem; 2024; 31(25):4034-4055. PubMed ID: 38685772 [TBL] [Abstract][Full Text] [Related]
3. Investigating the prognostic value of constructing disulfidptosis-related gene models for lung adenocarcinoma patients. Luo M; Liu RZ; Li YJ; Zhang SD; Wu ZY Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):9569-9585. PubMed ID: 37916324 [TBL] [Abstract][Full Text] [Related]
4. Identification of a disulfidptosis-related genes signature for prognostic implication in lung adenocarcinoma. Huang J; Zhang J; Zhang F; Lu S; Guo S; Shi R; Zhai Y; Gao Y; Tao X; Jin Z; You L; Wu J Comput Biol Med; 2023 Oct; 165():107402. PubMed ID: 37657358 [TBL] [Abstract][Full Text] [Related]
5. A disulfidptosis-related lncRNA prognostic model to predict survival and response to immunotherapy in lung adenocarcinoma. Zhang HB; Pan JY; Zhu T Front Pharmacol; 2023; 14():1254119. PubMed ID: 37822882 [No Abstract] [Full Text] [Related]
6. Identification of disulfidptosis-related subgroups and prognostic signatures in lung adenocarcinoma using machine learning and experimental validation. Wang Y; Xu Y; Liu C; Yuan C; Zhang Y Front Immunol; 2023; 14():1233260. PubMed ID: 37799714 [TBL] [Abstract][Full Text] [Related]
7. Role of disulfidptosis in colorectal adenocarcinoma: implications for prognosis and immunity. Yang R; Lai C; Huang L; Li F; Peng W; Wu M; Xin J; Lu Y; Ouyang M; Bai Y; Lei H; He S; Lin Y Front Immunol; 2024; 15():1409149. PubMed ID: 39399504 [TBL] [Abstract][Full Text] [Related]
8. Molecular map of disulfidptosis-related genes in lung adenocarcinoma: the perspective toward immune microenvironment and prognosis. Zhao F; Su L; Wang X; Luan J; Zhang X; Li Y; Li S; Hu L Clin Epigenetics; 2024 Feb; 16(1):26. PubMed ID: 38342890 [TBL] [Abstract][Full Text] [Related]
9. The expression and prognostic value of disulfidptosis progress in lung adenocarcinoma. Ni L; Yang H; Wu X; Zhou K; Wang S Aging (Albany NY); 2023 Aug; 15(15):7741-7759. PubMed ID: 37552140 [TBL] [Abstract][Full Text] [Related]
10. Construction of lncRNA prognostic model related to disulfidptosis in lung adenocarcinoma. Zhang L; Wang S; Wang L Heliyon; 2024 Aug; 10(15):e35657. PubMed ID: 39170273 [TBL] [Abstract][Full Text] [Related]
11. Identifying and assessing a prognostic model based on disulfidptosis-related genes: implications for immune microenvironment and tumor biology in lung adenocarcinoma. Wang J; Liu K; Li J; Zhang H; Gong X; Song X; Wei M; Hu Y; Li J Front Immunol; 2024; 15():1371831. PubMed ID: 38840910 [TBL] [Abstract][Full Text] [Related]
12. Identification and validation of a disulfidptosis-related genes prognostic signature in lung adenocarcinoma. Zhang Y; Sun J; Li M; Hou L; Wang Z; Dong H; Xu W; Jiang R; Geng Y; Guan C; Zhu Z; Wang H; Gong Q; Zhang G Heliyon; 2024 Jan; 10(1):e23502. PubMed ID: 38223725 [TBL] [Abstract][Full Text] [Related]
13. Disulfidptosis-related gene Zhu J; Ge H; Chen Y; Zhang S; Wu J; Nai W; Min L Transl Cancer Res; 2024 Sep; 13(9):5064-5072. PubMed ID: 39430814 [TBL] [Abstract][Full Text] [Related]
14. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Liu X; Nie L; Zhang Y; Yan Y; Wang C; Colic M; Olszewski K; Horbath A; Chen X; Lei G; Mao C; Wu S; Zhuang L; Poyurovsky MV; James You M; Hart T; Billadeau DD; Chen J; Gan B Nat Cell Biol; 2023 Mar; 25(3):404-414. PubMed ID: 36747082 [TBL] [Abstract][Full Text] [Related]
15. Construction of a novel disulfidptosis-related signature for improving outcomes in hepatocellular carcinoma: Observational study. Chen X; Liang Q; Zhou Y Medicine (Baltimore); 2023 Oct; 102(40):e35423. PubMed ID: 37800779 [TBL] [Abstract][Full Text] [Related]
16. A novel disulfidptosis-related prognostic gene signature and experimental validation identify ACTN4 as a novel therapeutic target in lung adenocarcinoma. Xie K; Wang B; Pang P; Li G; Yang Q; Fang C; Jiang W; Feng Y; Ma H Cancer Biomark; 2024 Feb; ():. PubMed ID: 38517776 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic and prognostic effect of disulfidptosis-related genes in lung adenocarcinoma. Li C; Sun C; Li Y; Dong L; Wang X; Li R; Su J; Cao Q; Xin S Heliyon; 2024 Jul; 10(13):e33764. PubMed ID: 39050421 [TBL] [Abstract][Full Text] [Related]
18. Leveraging a disulfidptosis/ferroptosis-based signature to predict the prognosis of lung adenocarcinoma. Ma X; Deng Z; Li Z; Ma T; Li G; Zhang C; Zhang W; Chang J Cancer Cell Int; 2023 Nov; 23(1):267. PubMed ID: 37946181 [TBL] [Abstract][Full Text] [Related]
19. Molecular subtypes of disulfidptosis-regulated genes and prognosis models for predicting prognosis, tumor microenvironment infiltration, and therapeutic response in hepatocellular carcinoma. Qu J; Guan H; Zheng Q; Sun F Int J Biol Macromol; 2024 Mar; 261(Pt 1):129584. PubMed ID: 38246443 [TBL] [Abstract][Full Text] [Related]
20. Subtype classification based on t cell proliferation-related regulator genes and risk model for predicting outcomes of lung adenocarcinoma. Yang Q; Zhu W; Gong H Front Immunol; 2023; 14():1148483. PubMed ID: 37077919 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]